Prostate Cancer

We all hate cancer, but not all of us can afford to whip out our wallets or write a fat check to help fight the disease. But there is no need to feel helpless or guilty if you want to take a stand and fight for a cure. Here are five fantastic and FREE ways you can help cure cancer: Create a Facebook Fundraiser on Facebook! Your friends on Facebook are there because they care about you and want to see what you are up to and what you are interested in. By creating a Facebook fundraiser, you can help raise money for organizations that are working to cure cancer without spending any money of your own. Often, people who care about you will be inclined to support something you are clearly passionate about, especially if it is for a good cause. It can be particularly effective to donate your birthday on Facebook to great cancer-fighting organizations like the Prostate Cancer Foundation. Casual acquaintances may not be likely to send you a personal gift, but if they see you are trying to

June 25 (UPI) -- A new combination therapy has shown promise in effectively fighting prostate cancer, new research shows. Two targeted treatments reduced PSA levels in patients with prostate cancer and had fewer side effects than traditional therapies, according to a study presented Tuesday at the Society of Nuclear Medicine and Molecular Imaging. "The initial results of this phase I dose escalation study show that the combination targeted treatments were well tolerated together, with no increase in toxicity from 177Lu PSMA 617, and an apparent high efficacy in men who have already had extensive treatments," said Louise Emmett, associate professor at the University of New South Wales in Australia and study author, in a news release. After enrolling 16 men with progressing metastatic castrate-resistant prostate cancer. The men took six doses of the targeted radionuclide therapy 177Lu PSMA 617 through six weeks. Then the researchers decided to add another therapy to

Arnulf Stenzl, MD Enzalutamide (Xtandi) in combination with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) demonstrated significantly improved radiographic progression-free survival (rPFS) versus placebo plus ADT, regardless of baseline prostate-specific antigen (PSA) levels, according to expanded findings from the ARCHES study. 1 The PSA finding is important finding because baseline levels are considered a strong prognostic indicator for clinical outcomes in men with mHSPC following ADT, 2 Arnulf Stenzl, MD, said in presenting the data during the American Urological Association 2019 Annual Meeting. 1 The results suggest the limitations of baseline PSA as a predictive factor among patients who have received prior ADT, Stenzl and colleagues said in their conference abstract. At the same time, strong improvements in the PSA-related endpoints of time to PSA progression, PSA reduction from baseline, and PSA undetectable rate were

A recent review compared the use of decision aids versus usual care in men choosing to undergo prostate cancer screening . The researchers found that there is no strong evidence favoring the use of decision aids in this population. The choice of whether or not to undergo prostate cancer screening would ideally be made through shared decision-making, according to the researchers—although this is not always an option. “Shared decision-making is challenging because of time constraints and the specific skills that it requires,” wrote the study authors, reporting in JAMA Internal Medicine . “Well-designed decision aids may, at least in part, address these challenges by summarizing the current best evidence and by supporting conversations that address the issues that matter most to patients.” For the review, researchers queried MEDLINE, Embase, CINAHL, PsychINFO, and Cochrane Central Register of Controlled Trials for relevant randomized controlled trials (RCTs). Studies focused on men

The purpose of this study was to determine the association of marital status, a marker of social support, with all-cause and prostate cancer-specific mortality in a cohort of men with early-stage prostate cancer treated with radical prostatectomy. We conducted a retrospective cohort study of 3,579 men treated for localized (stage 1-2) prostate cancer with radical prostatectomy at a single institution between 1994 and 2004. Marital status (not married vs. married) and marital history (never married, divorced, widowed vs. married) at the time of prostatectomy were examined in relation to (1) all-cause mortality and (2) prostate cancer-specific mortality using Cox proportional hazards regression. Not being married (vs. married) at the time of radical prostatectomy was associated with an increased risk of all-cause mortality [Hazard Ratio (HR) 1.42; 95% Confidence Interval (CI) 1.10, 1.85]. Similarly, in analyses of marital history, never-married men were at highest risk of all-cause mor

The higher incidence of prostate cancers in responders to the attacks in New York City that occurred on September 11, 2001, may be related to responders' exposure to the dust generated from the collapse of the World Trade Center (WTC) towers. This dust may have caused changes in inflammatory and immune regulatory mechanisms in prostate tissue, a new study suggests. " Prostate cancer is one of the cancers that is significantly higher in first responders, and we wanted to understand why," said study author Emanuela Taioli, MD, PhD, director of the Institute for Translational Epidemiology at the Icahn School of Medicine at Mount Sinai and associate director for population science at the Tisch Cancer Institute, both in New York City. "For the first time, we think we have discovered the underlying mechanism." She explained that prostate cancer tissue samples from responders showed a higher degree of expression of immunologic and inflammatory genes than tissue sam

June 25 (UPI) -- A new combination therapy has shown promise in effectively fighting prostate cancer, new research shows. Two targeted treatments reduced PSA levels in patients with prostate cancer and had fewer side effects than traditional therapies, according to a study presented Tuesday at the Society of Nuclear Medicine and Molecular Imaging. "The initial results of this phase I dose escalation study show that the combination targeted treatments were well tolerated together, with no increase in toxicity from 177Lu PSMA 617, and an apparent high efficacy in men who have already had extensive treatments," said Louise Emmett, associate professor at the University of New South Wales in Australia and study author, in a news release. After enrolling 16 men with progressing metastatic castrate-resistant prostate cancer. The men took six doses of the targeted radionuclide therapy 177Lu PSMA 617 through six weeks. Then the researchers decided to add another therapy to

New prostate cancer research shows that adding an interim scan during therapy can help guide a patient's treatment. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging of patients with metastatic castration-resistant prostate cancer after two cycles of lutetium-177 (177Lu)-PSMA radioligand therapy has shown a significant predictive value for patient survival. The research was presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). According to the National Cancer Institute, currently the five-year survival rate for men with metastatic prostate cancer is 30.5 percent. Early assessment of treatment effectiveness is essential to providing optimal care. In phase 2 trials, 177Lu-PSMA therapy has shown promising results in treating patients with metastatic castration-resistant prostate cancer. The therapy typically involves a preliminary PSMA PET scan to identify patients who are eligible for the treatment

Arnulf Stenzl, MD Enzalutamide (Xtandi) in combination with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) demonstrated significantly improved radiographic progression-free survival (rPFS) versus placebo plus ADT, regardless of baseline prostate-specific antigen (PSA) levels, according to expanded findings from the ARCHES study. 1 The PSA finding is important finding because baseline levels are considered a strong prognostic indicator for clinical outcomes in men with mHSPC following ADT, 2 Arnulf Stenzl, MD, said in presenting the data during the American Urological Association 2019 Annual Meeting. 1 The results suggest the limitations of baseline PSA as a predictive factor among patients who have received prior ADT, Stenzl and colleagues said in their conference abstract. At the same time, strong improvements in the PSA-related endpoints of time to PSA progression, PSA reduction from baseline, and PSA undetectable rate were

New prostate cancer research shows that adding an interim scan during therapy can help guide a patient's treatment. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging of patients with metastatic castration-resistant prostate cancer after two cycles of lutetium-177 (177Lu)-PSMA radioligand therapy has shown a significant predictive value for patient survival. The research was presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). According to the National Cancer Institute, currently the five-year survival rate for men with metastatic prostate cancer is 30.5 percent. Early assessment of treatment effectiveness is essential to providing optimal care. In phase 2 trials, 177Lu-PSMA therapy has shown promising results in treating patients with metastatic castration-resistant prostate cancer. The therapy typically involves a preliminary PSMA PET scan to identify patients who are eligible for the treatment

The higher incidence of prostate cancers in responders to the attacks in New York City that occurred on September 11, 2001, may be related to responders' exposure to the dust generated from the collapse of the World Trade Center (WTC) towers. This dust may have caused changes in inflammatory and immune regulatory mechanisms in prostate tissue, a new study suggests. " Prostate cancer is one of the cancers that is significantly higher in first responders, and we wanted to understand why," said study author Emanuela Taioli, MD, PhD, director of the Institute for Translational Epidemiology at the Icahn School of Medicine at Mount Sinai and associate director for population science at the Tisch Cancer Institute, both in New York City. "For the first time, we think we have discovered the underlying mechanism." She explained that prostate cancer tissue samples from responders showed a higher degree of expression of immunologic and inflammatory genes than tissue sam

New prostate cancer research shows that adding an interim scan during therapy can help guide a patient's treatment. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging of patients with metastatic castration-resistant prostate cancer after two cycles of lutetium-177 (177Lu)-PSMA radioligand therapy has shown a significant predictive value for patient survival. The research was presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). According to the National Cancer Institute, currently the five-year survival rate for men with metastatic prostate cancer is 30.5 percent. Early assessment of treatment effectiveness is essential to providing optimal care. In phase 2 trials, 177Lu-PSMA therapy has shown promising results in treating patients with metastatic castration-resistant prostate cancer. The therapy typically involves a preliminary PSMA PET scan to identify patients who are eligible for the treatment

A recent review compared the use of decision aids versus usual care in men choosing to undergo prostate cancer screening . The researchers found that there is no strong evidence favoring the use of decision aids in this population. The choice of whether or not to undergo prostate cancer screening would ideally be made through shared decision-making, according to the researchers—although this is not always an option. “Shared decision-making is challenging because of time constraints and the specific skills that it requires,” wrote the study authors, reporting in JAMA Internal Medicine . “Well-designed decision aids may, at least in part, address these challenges by summarizing the current best evidence and by supporting conversations that address the issues that matter most to patients.” For the review, researchers queried MEDLINE, Embase, CINAHL, PsychINFO, and Cochrane Central Register of Controlled Trials for relevant randomized controlled trials (RCTs). Studies focused on men

New prostate cancer research shows that adding an interim scan during therapy can help guide a patient's treatment. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging of patients with metastatic castration-resistant prostate cancer after two cycles of lutetium-177 (177Lu)-PSMA radioligand therapy has shown a significant predictive value for patient survival. The research was presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). According to the National Cancer Institute, currently the five-year survival rate for men with metastatic prostate cancer is 30.5 percent. Early assessment of treatment effectiveness is essential to providing optimal care. In phase 2 trials, 177Lu-PSMA therapy has shown promising results in treating patients with metastatic castration-resistant prostate cancer. The therapy typically involves a preliminary PSMA PET scan to identify patients who are eligible for the treatment

Abstract PURPOSE: Patient-reported outcomes after radical prostatectomy have focused on erectile function. To date, no studies have validated the Patient-Reported Outcome Measurement Information System (PROMIS) Sexual Interest and Satisfaction single item measures in patients with prostate cancer, nor have studies examined how these measures relate to erectile function. In addition, data are lacking with regard to the clinical responsiveness of these measures to treatment. We sought to validate and examine the clinical utility of these measures in men after radical prostatectomy. PATIENTS AND METHODS: We identified men who underwent a robotic radical prostatectomy from May 2014 to January 2016 in the Michigan Urological Surgery Improvement Collaborative. A single item from the PROMIS Global Satisfaction With Sex Life subdomain and a single item from the PROMIS Interest in Sexual Activity subdomain were administered. Erectile function was also assessed. Differences between baselin

As backyard cookout season kicks into high gear, many people may be eyeing their sizzling burgers and dogs with suspicion. And for good reason: a number of studies published in the past two decades have turned up evidence that eating charred, smoked, and well-done meat could raise cancer risk—pancreatic, colorectal, and prostate cancers, in particular. A 2010 review of the evidence on cancer and “well-done” meat, conducted by researchers at Vanderbilt University, concluded that “the majority of these studies have shown that high intake of well-done meat and high exposure to meat carcinogens, particularly HCAs, may increase the risk of human cancer.” Heterocyclic amines (HCAs), which some experts also refer to as heterocyclic aromatic amines (HAAs), are a class of chemical that forms in cooked red meat and, to a lesser extent, in poultry and fish, according to a 2011 study in the journal Chemical Research in Toxicology . Another class of chemicals, called polycyclic aromatic hydroc

The purpose of the study was to determine the relationship between family history of prostate cancer in a first-degree relative (FDR) and prostate cancer incidence and mortality. Deidentified data sets of men recruited in the Prostate, Lung, Colorectal, and Ovary (PLCO) trial were accessed. Men with complete information about family history of prostate cancer in an FDR were included. The effect of family history on prostate cancer incidence and mortality was assessed in a multivariate Cox regression model. Likewise, the effect of the number of FDRs with prostate cancer and the effect of youngest diagnosis age of an FDR with prostate cancer were assessed. A total of 74,781 participants were included in the current analysis, including 5281 participants with family history of prostate cancer in an FDR and 69,500 participants without family history of prostate cancer in an FDR. Among participants without family history of prostate cancer in an FDR, a total of 7450 patients (10.5%) were s

PANAMA CITY, Fla. – Men with advanced prostate cancer in the greater Panama City area now have greater access to immunotherapy treatment thanks to a new cell collection (or apheresis) in the Florida panhandle. Men prescribed immunotherapy for advanced prostate cancer need to visit a cell collection center to have their cells extracted – a critical part of delivering a treatment that is customized for each person. Nearly 13,000 men in Florida are living with prostate cancer, including an estimated 127 men from Bay County alone. Men with prostate cancer often survive 15 years or longer after learning they have the disease, but prostate cancer remains one of the five most common cancers and the second most frequent cause of cancer-related death among men. A number of new treatment options, including anti-androgen therapy, radiopharmaceuticals, chemotherapy and immunotherapy, show new promise for men in the advanced stages of the disease – those whose cancer recurs after radiation or su

Please enable Javascript to watch this video BIRMINGHAM, Alabama – It may not seem like much, but to Mickey Nunn, being able to play bass guitar for his wife Teresa is a big miracle. More than ten years ago, he was diagnosed with stage four prostate cancer. The cancer was inoperable and Mickey had already undergone 42 treatments of radiation. So now he had 17 rounds of chemotherapy. "Chemo for me was like throwing it on the wall and seeing if it stuck." According to the American Cancer Society, one in nine men will be diagnosed with prostate cancer at some point during his lifetime. Even with all the treatments, his PSA score, or prostate-specific antigen sky-rocketed. A score above four is a risk factor for prostate cancer.    Mickey's was 99. "Only thing that was left was to pray to God for a miracle and he gave me one." University of Alabama Birmingham Dr. Eddy Yang believes he can treat Mickey's tumor using precision medicine. &quo

The individual risk to progression is unclear for intermediate risk prostate cancer patients. To assess their risk to progression, we examined the level of genomic instability in circulating tumor cells (CTCs) using quantitative three-dimensional (3D) telomere analysis. Data of CTCs from 65 treatment-naïve patients with biopsy-confirmed D'Amico-defined intermediate risk prostate cancer were compared to radical prostatectomy pathology results, which provided a clinical endpoint to the study and confirmed pre-operative pathology or demonstrated upgrading. Hierarchical centroid cluster analysis of 3D pre-operative CTC telomere profiling placed the patients into three subgroups with different potential risk of aggressive disease. Logistic regression modeling of the risk of progression estimated odds ratios with 95% confidence interval (CI) and separated patients into "stable" vs. "risk of aggressive" disease. The receiver operating characteristic (ROC) curve showed

Decision aids appeared to have no measurable effect on prompting patient-physician discussions about prostate cancer screening or on influencing whether men actually underwent prostatic specific antigen (PSA) testing, a systematic review and meta-analysis found. In analyzing results from 19 randomized controlled trials, the median frequency with which men discussed PSA testing with their doctor was 52% in studies where decision aids were used compared with 47% in usual care groups (risk ratio [RR] 1.12, 95% CI 0.90-1.39, I 2 = 60%), Kari Tikkinen, MD, PhD, of Helsinki University Hospital in Finland, and colleagues reported. Furthermore, regarding patients' decision to undergo PSA testing, no association was seen between use of a decision aid versus usual care (RR 0.95, 95% CI 0.88-1.03, I 2 = 36%), as described in JAMA Internal Medicine . At best, the meta-analysis found evidence that use of decision aids "probably" decreased patient conflict about screening and &qu

New prostate cancer research shows that adding an interim scan during therapy can help guide a patient's treatment. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging of patients with metastatic castration-resistant prostate cancer after two cycles of lutetium-177 (177Lu)-PSMA radioligand therapy has shown a significant predictive value for patient survival. The research was presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). According to the National Cancer Institute, currently the five-year survival rate for men with metastatic prostate cancer is 30.5 percent. Early assessment of treatment effectiveness is essential to providing optimal care. In phase 2 trials, 177Lu-PSMA therapy has shown promising results in treating patients with metastatic castration-resistant prostate cancer. The therapy typically involves a preliminary PSMA PET scan to identify patients who are eligible for the treatmen